NAD+ IV Therapy vs Subcutaneous Injection: When Each Makes Sense

The short answer

NAD+ IV therapy and subcutaneous NAD+ injection deliver the same molecule into the same circulation. The differences are dose per session, clinical setting, peak plasma curve, and cost.

IV delivers a 500 to 1500 mg dose over 60 to 90 minutes in a clinic at $500 to $1500 per session. Subcutaneous injection is done at home in about 30 seconds, and at the 20 mg starting protocol a $100 vial holds roughly 50 doses. The cost gap is real and large. What does not follow is that a weekly total by one route equals the same total by the other: equal milligrams do not imply equal absorption, distribution or effect, and no study has measured that for subcutaneous NAD+.

IV is the right tool for acute loading: addiction recovery, severe chronic fatigue protocols, and longevity-stack initiation. Injection is the right tool for maintenance, on-going restoration in adults over 40, and any protocol that runs more than a month. Many patients start with IV loading at a clinic and transition to home injection for maintenance.

What NAD+ IV therapy actually is

NAD+ IV therapy is delivery of nicotinamide adenine dinucleotide directly into a peripheral vein over a 60 to 90 minute drip. Doses range from 500 mg to 1500 mg per session. The molecule enters systemic circulation immediately, with peak plasma NAD+ during the drip itself and gradual decline over the following 24 to 72 hours.

Most clinics deliver NAD+ IV in an IV-lounge setting alongside related infusions (hydration, B-vitamins, glutathione, vitamin C). A clinician supervises. The drip rate is throttled to control the flushing and chest-tightness reaction NAD+ causes at higher infusion rates. Slower drips are more comfortable; faster drips finish in 45 minutes but are harder to tolerate.

What subcutaneous NAD+ injection is

Subcutaneous NAD+ injection is delivery of the same molecule into the fat layer beneath the skin using a small insulin syringe. The RxPepsDirect starting protocol is 20 units, which is 0.2mL from the 100 mg/mL vial, or 20 mg. Higher figures circulate online, but the syringe sets a hard limit worth knowing: 100 mg fills a U-100 insulin syringe completely and 200 mg is 2mL, which cannot be drawn into one at all. Your label and prescriber set the dose.

Reported flushing is generally milder than with IV infusion, which is usually attributed to slower absorption from the subcutaneous depot, though the absorption profile itself has not been measured in published human research. Most patients adapt to the sensation within the first few doses.

RxPepsDirect ships NAD+ Injectable pre-reconstituted in 1000 mg multi-dose vials. Each vial covers roughly 5 weeks of twice-weekly maintenance dosing at 200 mg per injection.

Cost comparison

What is known about each route

IV administration places the dose directly into circulation, which is not in dispute. Beyond that, the honest position is that the comparison cannot be made. Subcutaneous NAD+ has no published human pharmacokinetic study, so its absorption, plasma curve, area under the curve and tissue delivery are not established. Without that, statements that the two routes produce comparable weekly exposure, equivalent area under the curve, or similar tissue NAD+ status are assertions rather than findings, however often they are repeated.

Matching milligrams does not settle it either. Equal totals by different routes do not imply equal absorption, metabolism, intracellular delivery, duration or clinical effect. A 2019 pilot characterised the human plasma and urine metabolome during a six-hour IV NAD+ infusion, and a 2026 retrospective reported tolerability in a commercial IV setting, but neither establishes outcomes, and no equivalent work exists for the subcutaneous route.

What can be compared without overreaching: cost, time, setting, who supervises the dose, and how each fits a schedule. Those are the grounds on which this decision can actually be made today. NAD+ is not an FDA-approved treatment for substance-use disorder, and it should not be presented as a substitute for evidence-based addiction care.

Patient experience: clinic vs home

The IV experience is a 60 to 90 minute clinic visit, typically in a recliner alongside other patients receiving infusions. A clinician places the IV, throttles the drip rate, and monitors for reaction. Some patients enjoy the dedicated time and the IV-lounge social context. Others find the time commitment and the cost prohibitive for ongoing therapy. If you are deciding between a local drip and a shipped at-home protocol, our guide to peptide therapy clinics near you weighs the in-person and telehealth routes.

The injection experience is 30 seconds at home, usually performed in the morning or before exercise. Patients rotate injection sites (abdomen, thigh, upper arm) and follow the prescriber’s written protocol. Most patients find the routine easy to maintain once they adapt to the injection sensation in the first few doses.

Who genuinely benefits from IV

• Acute addiction recovery protocols. The traditional NAD+ recovery loading dose is 1500 mg per day for 5 to 10 consecutive days. This dose is hard to replicate with subcutaneous injection alone. IV is the established clinical tool for this protocol.
• Severe chronic fatigue or post-viral protocols. Some chronic fatigue clinics use weekly high-dose IV NAD+ to jumpstart mitochondrial function. The acute peak plasma level appears clinically useful in this population.
• Longevity-stack initiation in the first 4 to 8 weeks. Patients starting a longevity peptide stack often use IV NAD+ as a loading phase before transitioning to home injection for maintenance. The mental model is similar to loading a creatine stack: front-load the tissue saturation, then maintain with smaller doses.
• Patients who explicitly want clinical supervision. Some patients value the in-clinic experience, the monitoring, and the social context of the IV lounge. For those patients the premium is justified by preference.

Who should choose subcutaneous injection

• Ongoing use where cost is the deciding factor. Subcutaneous injection is far cheaper per dose and needs no clinic visit. That is a practical argument, not a claim that it delivers the same thing as an infusion.
• Anyone who prefers a route they can supervise at home. NAD+ does decline with age, but how much varies by tissue, measurement method and health status, and a 2025 review found the human tissue data sparse enough to warn against extrapolating from animal work. No age group is an established responder group, so age alone should not drive the choice.
• Patients optimizing a longevity stack. Once a loading phase is complete (whether via IV or initial high-dose injection), maintenance is best handled at home.
• Patients without easy access to a quality IV clinic. Many regions do not have a clinic that delivers NAD+ IV at reasonable cost or quality. At-home injection removes the geography problem.
• Anyone budget-conscious. $80 a month versus $1000 to $6000. The cost difference is dramatic. Whether the delivery difference is small is not known, since subcutaneous NAD+ has no published human pharmacokinetic data, so treat cost and convenience as the honest reasons to choose it.

The hybrid protocol some patients use

A common approach is to start with 2 to 4 IV sessions at a clinic over the first 4 to 8 weeks (loading phase), then transition to twice-weekly home subcutaneous injection for ongoing maintenance. This captures the acute peak of IV during initiation when the tissue shortage is largest and the patient is most attentive to subjective change, then settles into the cost-rational home routine once tissue NAD+ is closer to youthful baseline.

For most patients in their late 40s and beyond, the hybrid is more dramatic-feeling than pure home injection in the first 4 to 8 weeks because the acute peak produces stronger subjective effect. For younger patients or those with smaller cellular shortage, pure home injection is usually adequate from the start.

Ready to start

For at-home subcutaneous NAD+, the RxPepsDirect peptide list has NAD+ Injectable at $100 per 1000 mg vial. For needle-free dosing, NAD+ Nasal Spray covers maintenance and on-demand cognitive use. For more detail on subcutaneous injection logistics see how to get NAD+ injections online. For the broader benefits picture see what NAD+ actually does.